European Primary Care Cardiovascular Society

Prevention of atherosclerotic CV events with cholesterol absorption inhibitor in older patients

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.

2nd edition of physical activity guidelines for Americans released by U.S. Department of Health & Human Services

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.

No reduction in major CVD events with omega-3s or vitamin D in primary prevention cohort

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.

Improved quality of life but not CV events with yoga-based cardiac rehabilitation post-MI

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.

Lower risk of ischemic events with triglyceride-lowering agent in hypertriglyceridemic patients on statins

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 In the randomized REDUCE-IT trial, daily treatment with icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowered CV events in primary and secondary prevention of hypertriglyceridemic patients.

More focus on personalized risk assessment in updated AHA/ACC cholesterol guidelines

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

AHA 2018